Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Find the Historical backdrop of Common liberties: Advancing Equity and Equity Around the world - 2Trump said affordability is a ‘hoax’ in his Pennsylvania speech. What do the latest numbers show?
- 375% of US adults may meet criteria for obesity under new definition, study finds
- 46 Exemplary Mexican Dishes
- 5Google's proposed data center in orbit will face issues with space debris in an already crowded orbit
- Top 5 Top of the line Books of the Year
- Fact Check: Some Bridge Photos Circulating Do NOT Show The Hongqi Bridge That Collapsed In Southwest China Nov. 11, 2025
- Europe's powerful Ariane 6 rocket launches Sentinel-1D Earth-observation satellite to orbit (video)
- Watch SpaceX launch powerful ocean-mapping satellite for Europe and NASA early Nov. 17
- 4K televisions for Extreme Film Watching Experience
- Chris Noth responds to backlash after seemingly shading 'Sex and the City' costar Sarah Jessica Parker: 'It is not news'
- Artemis 2 breaks humanity's all-time distance record during historic loop around the moon (video)
- 15 Outrageous Cosplay Outfits That Will Blow You Away
- Instructions to Keep up with Your Traded Teeth for Life span
